About
Pharmability (formerly TIRmed) is developing advanced targeted therapies for atopic dermatitis (eczema), aiming to address underlying disease mechanisms to provide more effective and long‑lasting relief. The company is focused on next‑generation pharmaceutical approaches for dermatological indications.
Explore Pharmability's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.